Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Olivia Manser - Director-Investor Relations
Christian Itin - Chief Executive Officer
Rob Dolski - Chief Financial Officer

Conference Call Participants

James Shin - Deutsche Bank
Matthew Phipps - William Blair
Sebastiaan van der Schoot - VLK
Hanze Zu - Jefferies
Gil Blum - Needham & Company
Jacob Mekhael - KBC Securities

Operator

Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Third Quarter 2024 Financial Results and Business Updates. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn this conference over to your host, Olivia Manser. Please go ahead.

Olivia Manser

Thanks, Jacinda. Good morning or good afternoon, everyone, and thanks for joining us on our Q3 2024 call today. With me today are Dr. Christian Itin, our Chief Executive Officer; Rob Dolski, our Chief Financial Officer; and Chris Vann, our Chief Operating Officer.

And so on to slide 2 our disclaimers. As a reminder, during today's call we will make statements related to our business that are forward-looking under federal securities laws and the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to statements regarding the expected timing for the commercial launch of AUCATZYL, Autolus manufacturing sales and marketing plans for AUCATZYL, including potential refinements at The Nucleus, the market potential for AUCATZYL, and the status of clinical trials and development and/or regulatory timelines for obe-cel and our other product candidates.

These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements.

For a discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and our SEC filings, which are available on the Investor section of our website.

On slide 3, we have the agenda. As usual Christian is going to give you an overview of our operational highlights, Rob will discuss the financial results, and we will then conclude with upcoming milestones and closing remarks and move on to Q&A. As I mentioned we have Chris Vann, our Chief Operating Officer also available for Q&A today.